Business context and reporting period
This Form 10-Q covers the quarter and nine months ended September 30, 2016. The registrant named in the filing is Emerald Medical Applications Corp., a digital-health company developing and marketing DermaCompare skin-imaging and analytics software. The request metadata names Quantum X Labs Inc.; that does not match the registrant identified in this filing and should be verified.
Financial results and position
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating expenses | $733,275 | $6,578,915 | $3,797,361 | $7,000,706 |
| Operating loss | $733,275 | $6,578,915 | $3,797,361 | $7,000,706 |
| Net loss | $675,371 | $7,234,711 | $3,763,575 | $7,675,156 |
| Basic and diluted loss per share | $0.03 | $0.54 | $0.20 | $0.81 |
No revenue was reported, so revenue or profit margins are not meaningful. Nine-month operating cash use was $802,867, versus $831,984 in the prior-year period. Financing provided $783,049, primarily from convertible notes; investing cash flow was zero. Cash declined by $43,682 to $71,767.
At September 30, 2016, current assets were $77,334 and current liabilities were $507,723, producing negative working capital of $430,389. Total assets were $95,062, liabilities $507,723, and stockholders’ deficit $412,661. Convertible notes are reported at $290,391 net of discount on the balance sheet; accrued interest payable was $20,310. The filing also reports $186,000 of contingent royalty obligations related to Israeli research grants. No clear debt maturity schedule for all outstanding notes is provided.
Changes versus the prior comparable period
- Nine-month net loss narrowed by about $3.9 million, largely alongside lower stock-based compensation ($2.77 million versus $5.34 million) and lower general and administrative expense. Q3 stock-based compensation fell to $371,715 from $5.34 million.
- Research and development expense declined to $450,688 for nine months from $499,898; general and administrative expense declined to $579,850 from $1,157,720.
- Cash fell from $115,449 at December 31, 2015 to $71,767. Current liabilities rose from $288,775 to $507,723, and negative working capital widened from $147,529.
- Debt discount amortization of $211,715 was recorded in the first nine months of 2016; there was no comparable expense in 2015. The prior-year period included a $678,027 loss on debt settlement.
Outlook, commentary, and risks
- Management said the company may need up to an additional $1.5 million over the next 12 months to fund operations and implement its business plan. It reported marketing efforts and continued distribution discussions, but no revenue had been generated through September 30.
- The filing contains an outdated expectation of significant revenue commencing in or before the first half of fiscal 2016; actual reported revenue through the period was zero. No current quantified revenue guidance is provided.
- Management states that cash resources are insufficient for the current business plan and that negative working capital and continuing losses raise substantial doubt about the company’s ability to continue as a going concern. Continued operations depend on obtaining additional financing.
- Disclosure controls and procedures were judged ineffective as of September 30, 2016. Management said corrective actions were planned for Q4 2016.
- The company terminated its equity purchase agreement with Kodiak Capital on October 10, 2016. The filing also reports management changes and a change in independent auditor during 2016.
- No legal proceedings were reported. The filing reports no trading or hedging activity in financial instruments.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for Emerald Medical Applications Corp., not Quantum X Labs Inc.
- Reconcile the convertible-note figures: the balance sheet reports $290,391 net, while Note 8 states $337,971 net of discount; the filing does not clearly resolve the difference.
- Reconcile financing proceeds: the cash-flow statement reports $783,049, while MD&A also cites $783,054.
- Ask what comprises the reported $186,615 of Q3 other income and $215,202 for nine months; the filing does not clearly explain the source.
- Assess near-term financing needs, potential dilution from convertible notes and warrants, and the company’s ability to meet obligations given its cash balance and going-concern warning.
- Verify progress on the ineffective-control remediation plan and the status of the auditor transition.